NANO BIOTHERAPEUTICS INC

Biotech · Private

Piceatannol-entrapped albumin nanoparticles (PANPs) for intravenous delivery to treat sepsis-induced acute lung injury

Grants
$4.4M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Albumin Nanoparticles Incorporating Piceatannol (PANPs) for ALI/ARDS therapy$2,699,089
Federal grantDepartment of Health and Human Services · Phase II · Albumin Nanoparticles Incorporating Piceatannol (PANPs) for ALI/ARDS therapy$867,135
Federal grantDepartment of Health and Human Services · Phase II · Albumin Nanoparticles Incorporating Piceatannol (PANPs) for ALI/ARDS therapy$872,742
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1364DOOR PHARMACEUTICALS, LLC——
1365ADECTO PHARMACEUTICALS, INC.——
1366WEATHERWAX BIOTECHNOLOGIES CORPORATION——
1367NANO BIOTHERAPEUTICS INC——
1368ARTUS THERAPEUTICS INC.——
1369Curebiotech, Inc.——
1370BOUND THERAPEUTICS LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.